ProShare Advisors’s Cardlytics CDLX Stock Holding History

ProShare Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,170	Closed	-$43.4K	–	2119
2024 Q4	$43.4K	Buy	+1,170	New	+$44.8K	﹤0.01%	2195
2022 Q2	–	Sell	-607	Closed	-$334K	–	1838
2022 Q1	$334K	Sell	607 -100	-14%	-$60.4K	﹤0.01%	1547
2021 Q4	$467K	Buy	707 +297	+72%	+$227K	﹤0.01%	1504
2021 Q3	$344K	Sell	410 -420	-51%	-$426K	﹤0.01%	1449
2021 Q2	$1.05M	Buy	830 +32	+4%	+$36.1K	﹤0.01%	1009
2021 Q1	$875K	Buy	798 +218	+38%	+$288K	﹤0.01%	1072
2020 Q4	$828K	Buy	580 +259	+81%	+$276K	﹤0.01%	966
2020 Q3	$227K	Sell	321 -30	-9%	-$21.8K	﹤0.01%	1348
2020 Q2	$246K	Buy	+351	New	+$203K	﹤0.01%	1343

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ProShare Advisors's CDLX Position: Q1 2025 in Review

ProShare Advisors sold out of Cardlytics (CDLX) in Q1 2025, closing a stake of 1,170 shares — an estimated $43.4K sold.

ProShare Advisors first reported a position in CDLX in Q2 2020 and held it in 9 quarters. The position peaked at $1.05M in Q2 2021. 108 funds tracked by Wall St. Rank hold CDLX as of Q1 2025.

ProShare Advisors reported no remaining Cardlytics position as of Q1 2025 after selling out during the quarter.
ProShare Advisors sold 1,170 Cardlytics shares in Q1 2025, an estimated $43.4K.
ProShare Advisors first reported a position in Cardlytics in Q2 2020 and held it in 9 quarters.
ProShare Advisors's Cardlytics position peaked at $1.05M in Q2 2021.
108 funds tracked by Wall St. Rank held Cardlytics as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.